Rexahn Represents An Attractive Investment Opportunity, Says Roth Capital
In a research report released July 18, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Rexahn Pharmaceuticals (RNN) with a $3 price target, following RNN’s recent update on the company’s Phase I dose-escalation study of Supinoxin in solid tumors.
Pantginis commented: “We are encouraged by the ongoing progress in this Phase I study of Supinoxin and look forward to the study completion and release of clinical data expected in 4Q14. We are also looking forward to the progress in the two other clinicalstage programs of Archexin, an Akt1 inhibitor and RX-3117, a DNA synthesis inhibitor. A Phase IIa study of Archexin in pancreatic cancer showed that the drug is safe and well tolerated and demonstrated preliminary signs of efficacy. Archexin is in an ongoing Phase IIa study in metastatic renal cell carcinoma (mRCC). The safety component for this study should be completed in 4Q14. RX-3117 has successfully completed an exploratory Phase I study in solid tumors and is in a Phase Ib study in patients with solid tumors. Enrollment in the Phase I study should be complete in 4Q14/1Q15. Over the long term, we believe that Rexahn can drive value from its nano-polymer-drug conjugate system (NPDCS). Two lead candidates from this platform are 1) RX-21101 which is a polymer conjugated form of docetaxel and 2) RX-0201 which is a nanoliposomal Akt-1 inhibitor, which is similar to Archexin”.
The analyst concluded, “We believe a compelling valuation for the stock is being driven by the required pieces now in place for this refocused and retooled story. With a sole focus on oncology, we believe that Rexahn’s increasing visibility going forward represents an attractive investment opportunity.
According to TipRanks.com, which measures analysts and bloggers success rate based on how their calls perform, analyst Joseph Pantginis has a -11.9% average return and a 24% success rate. Pantginis has a -27% average return when recommending RNN, and is ranked #3194 out of 3215 analysts.